• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Exelixis

Lifeline
Favicon Fierce Biotech

Midsize biotechs form coalition to fight against MFN policy

A group of 10 domestic, medium-sized biotechs launched the Midsized Biotech Alliance of America to advocate for free-market solutions to drug policy.
Will Maddox Feb 25, 2026 1:05pm
Morrissey

Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO

Jan 16, 2026 1:00pm
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Favicon Fierce Biotech

Exelixis plans shuttering of East Coast site, 130 layoffs

Aug 29, 2025 9:15am
FDA

FDA recognizes 'crossover impact' on survival in Cabometyx nod

Mar 26, 2025 11:03am
Exelixis

Exelixis shifts focus as triplet misses OS mark in kidney cancer

Feb 18, 2025 1:30pm
Cancelled

FDA cancels adcomm for Cabometyx in neuroendocrine tumors

Jan 10, 2025 9:46am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings